Project Grant R00HL168211
Award Date
5/16/25
Completion Date
4/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $712,167 to the University of Chicago to investigate opioid-induced respiratory depression (OIRD) and develop therapeutic strategies to mitigate this issue. The research aims to determine how the opioid fentanyl activates the carotid body, a key regulator of breathing, through kappa-opioid receptors, and assess whether...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) totaling $1,557,845 provides funding to the Regents of the University of Michigan to conduct research on the brainstem mechanisms underlying opioid-induced respiratory depression. The 4-year project aims to: Determine the synaptic targets of non-mu opioid receptor-expressing neurons in the dorsolateral pons that project to the ventrolateral...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $453,600.00 to the University of Chicago to investigate the cellular and systemic outcomes after reversing fentanyl-induced cardiorespiratory collapse (FICRC). The research aims to establish a foundational understanding of how factors beyond respiratory depression contribute to the progression of fentanyl overdose, leading to...
The National Institutes of Health (NIH) Office of the Director has awarded a $671,732 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Washington University in St. Louis. The 3-year grant, effective May 1, 2025, aims to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl-induced respiratory depression, the leading cause of opioid overdose deaths. Key objectives include assessing whether these...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $421,800.00 to Midwestern University to explore the effects of chronic intermittent hypoxia on cholinergic modulation at hypoglossal motoneurons. The project will use immunofluorescence and electrophysiology techniques to evaluate neuroanatomical and functional changes in cholinergic signaling at hypoglossal motoneurons in mice...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,704,286 to Texas A&M University System Health Science Center (TAMU HSC) to conduct research on overcoming opioid-induced respiratory depression (OIRD) in sleep apnea patients. The research aims to uncover the biological basis for why sleep apnea patients are more sensitive to the respiratory depressive effects of opioids, which is...
This K99/R00 Pathway to Independence Award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is designed to help the candidate establish an independent research career focused on the neural control of breathing. The award will support research to study how genetic factors, particularly APOE4, and inflammation influence mechanisms of respiratory motor plasticity using a well-studied model known as phrenic long-term...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $644,687 to the University of Missouri System to investigate a neural circuit involved in the peripheral chemoreflex and its contribution to hypertension following chronic intermittent hypoxia (CIH). The overarching goal is to use an integrative research approach, including chemogenetic and in vitro techniques, to resolve how an...
This National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research Program (CFDA 93.837) project grant provides $162,728 to the University of California, San Diego (UCSD) for the project period of January 1, 2025 to August 15, 2027. The grant will fund a mechanistic study to evaluate the underlying cardiovascular impacts of comorbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), referred to as overlap syndrome (OVS). The research aims to...